| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1158/1078-0432.CCR-06-2197 |
| P698 | PubMed publication ID | 17255300 |
| P2093 | author name string | Augusto C Ochoa | |
| Arnold H Zea | |||
| Paulo C Rodriguez | |||
| Claudia Hernandez | |||
| P433 | issue | 2 Pt 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 721s-726s | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma | |
| P478 | volume | 13 |
| Q40838791 | 17β-estradiol contributes to the accumulation of myeloid-derived suppressor cells in blood by promoting TNF-α secretion |
| Q27661305 | 2-Aminoimidazole Amino Acids as Inhibitors of the Binuclear Manganese Metalloenzyme Human Arginase I |
| Q34699543 | A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma |
| Q38918751 | Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses |
| Q34877332 | Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells |
| Q42750637 | Advances in radiotherapy and targeted therapies for rectal cancer |
| Q36410807 | Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. |
| Q64125847 | Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses |
| Q33733198 | Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. |
| Q34260335 | Anticancer effects of different seaweeds on human colon and breast cancers |
| Q46401930 | Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers |
| Q36267347 | Arginase I release from activated neutrophils induces peripheral immunosuppression in a murine model of stroke |
| Q34592559 | Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer |
| Q42670315 | Arginase Structure and Inhibition: Catalytic Site Plasticity Reveals New Modulation Possibilities |
| Q87642243 | Arginase and C-reactive protein as potential serum-based biomarker of head and neck squamous cell carcinoma patients of north east India |
| Q54265132 | Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation. |
| Q28396137 | Arginases and arginine deficiency syndromes |
| Q64986343 | Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. |
| Q35653129 | Bone marrow and the control of immunity |
| Q38185156 | Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy |
| Q46716170 | CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function |
| Q33585293 | CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets |
| Q35136030 | CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival |
| Q92151428 | CD247 expression is associated with differentiation and classification in ovarian cancer |
| Q52763511 | CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. |
| Q34784887 | COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells |
| Q33678308 | COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function |
| Q38719748 | CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma. |
| Q36060343 | Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset |
| Q37769017 | Cancer-associated myeloproliferation: old association, new therapeutic target |
| Q38208308 | Cancer: A Tale of Aberrant PRR Response |
| Q92970937 | Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment |
| Q28476714 | Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas |
| Q34477577 | Characterization of a novel population of low-density granulocytes associated with disease severity in HIV-1 infection |
| Q37644978 | Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. |
| Q37773282 | Chemokine-chemokine receptors in cancer immunotherapy |
| Q34579989 | Chronic intake of high fish oil diet induces myeloid-derived suppressor cells to promote tumor growth. |
| Q40946820 | Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. |
| Q38799063 | Circulating myeloid-derived suppressor cells in patients with pancreatic cancer |
| Q34560857 | Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients |
| Q49164235 | Contribution of Adipose Tissue to Development of Cancer. |
| Q36316728 | Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer |
| Q37719681 | Cotransplantation with myeloid-derived suppressor cells protects cell transplants: a crucial role of inducible nitric oxide synthase. |
| Q35546240 | CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. |
| Q37822746 | Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity |
| Q27662126 | Crystal Structure of Arginase from Plasmodium falciparum and Implications for l -Arginine Depletion in Malarial Infection, |
| Q27672035 | Crystal Structures of Complexes with Cobalt-Reconstituted Human Arginase I |
| Q38218134 | Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors |
| Q87634083 | Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress |
| Q35974328 | Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival |
| Q53191662 | Decreased number and reduced NKG2D expression of Vδ1 γδ T cells are involved in the impaired function of Vδ1 γδ T cells in the tissue of gastric cancer. |
| Q42368949 | Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine |
| Q83636423 | Dextran sulphate sodium increases splenic Gr1(+)CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation |
| Q37097116 | Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages |
| Q38993068 | Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. |
| Q33805313 | Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor |
| Q37494817 | Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. |
| Q37932437 | Dual biological effects of the cytokines interleukin-10 and interferon-γ. |
| Q92838353 | Dynamic changes in trauma-induced myeloid-derived suppressor cells after polytrauma are associated with an increased susceptibility to infection |
| Q45858579 | Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression |
| Q64080773 | Early myeloid-derived suppressor cells (HLA-DR/CD33CD16) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT |
| Q38212548 | Effects of obesity on immune responses to renal tumors |
| Q39896275 | Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function |
| Q38585850 | Emerging strategies for cancer immunoprevention |
| Q37593466 | Enhancing the efficacy of cancer vaccines in urologic oncology: new directions |
| Q35974911 | Epithelium Expressing the E7 Oncoprotein of HPV16 Attracts Immune-Modulatory Dendritic Cells to the Skin and Suppresses Their Antigen-Processing Capacity |
| Q35721553 | Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy |
| Q35162289 | Exosomes and cancer: a newly described pathway of immune suppression |
| Q27008452 | Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions |
| Q26865532 | From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors |
| Q34983887 | GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells |
| Q84875272 | Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation |
| Q33721765 | Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice |
| Q43110927 | Generation of myeloid-derived suppressor cells using prostaglandin E2. |
| Q50919779 | Gr-1(high) CD11b+ cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice. |
| Q88012863 | Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses |
| Q35448784 | Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level |
| Q64978993 | Granulocytic myeloid-derived suppressor cell population increases with the severity of alcoholic liver disease. |
| Q53160619 | Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients. |
| Q43180412 | Hepatic immune tolerance induced by hepatic stellate cells |
| Q36086084 | High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. |
| Q40449390 | Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas |
| Q51286736 | Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. |
| Q37872644 | How tumors might withstand γδ T-cell attack. |
| Q37287162 | How tumours escape mass destruction |
| Q34052492 | Human papillomavirus e7 oncoprotein transgenic skin develops an enhanced inflammatory response to 2,4-dinitrochlorobenzene by an arginase-1-dependent mechanism |
| Q37845226 | Hypoxia: a double-edged sword of immunity |
| Q35927462 | IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer |
| Q37317367 | Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. |
| Q54981236 | Immune consequences of anti-angiogenic therapyin renal cell carcinoma. |
| Q37040501 | Immune responses to malignancies |
| Q35201895 | Immune signature of tumor infiltrating immune cells in renal cancer |
| Q27027064 | Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences |
| Q37420586 | Immune-checkpoint blockade and active immunotherapy for glioma |
| Q35799185 | Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. |
| Q55360009 | Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses. |
| Q41920864 | Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer |
| Q37162897 | In Vitro and In Vivo Anticancer Effects of Sterol Fraction from Red Algae Porphyra dentata. |
| Q40551962 | Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia |
| Q42586000 | Increased B7-H1 and B7-H4 Expressions on Circulating Monocytes and Tumor-Associated Macrophages are Involved in Immune Evasion in Patients with Gastric Cancer. |
| Q44466098 | Increased circulating myeloid-derived suppressor cells correlated negatively with Th17 cells in patients with rheumatoid arthritis |
| Q36330142 | Increased level of arginase activity correlates with disease severity in HIV-seropositive patients |
| Q37704869 | Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients |
| Q90069431 | Increased regulatory B cells are involved in immune evasion in patients with gastric cancer |
| Q37375966 | Induction of myeloid-derived suppressor cells by tumor exosomes |
| Q50138585 | Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. |
| Q36337310 | Inflammatory malignant fibrous histiocytoma associated with leukemoid reaction or leukocytosis: a comprehensive review |
| Q39874482 | Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes |
| Q33903025 | Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression |
| Q24641894 | Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein |
| Q36561610 | Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model |
| Q53643579 | Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice. |
| Q28397886 | Integration of epidemiology, immunobiology, and translational research for brain tumors |
| Q37382352 | Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. |
| Q37964608 | Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy |
| Q28511526 | Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans |
| Q39592084 | Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. |
| Q45820540 | LPS converts Gr-1(+)CD115(+) myeloid-derived suppressor cells from M2 to M1 via P38 MAPK. |
| Q26850218 | Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention |
| Q38073753 | Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game |
| Q99546960 | Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine |
| Q33604925 | Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells |
| Q36718698 | Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway |
| Q37347953 | Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells |
| Q39045520 | Modulation of cancer-specific immune responses by amino acid degrading enzymes |
| Q37133654 | Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3 |
| Q52718963 | Murine Models of Hepatitis A Virus Infection. |
| Q37758250 | Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. |
| Q42408323 | Myeloid cells in tumor inflammation |
| Q89857326 | Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma |
| Q28082461 | Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy |
| Q36845851 | Myeloid derived suppressor cells: Targets for therapy |
| Q99711500 | Myeloid-Derived Suppressor Cells Promote the Progression of Primary Membranous Nephropathy by Enhancing Th17 Response |
| Q38528814 | Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer |
| Q89736292 | Myeloid-Derived Suppressor Cells and γδT17 Cells Contribute to the Development of Gastric MALT Lymphoma in H. felis-Infected Mice |
| Q89976160 | Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer |
| Q26749373 | Myeloid-Derived Suppressor Cells in Bacterial Infections |
| Q38931895 | Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases: Angel or Demon? |
| Q37778697 | Myeloid-Derived Suppressor Cells in Human Cancer |
| Q35141469 | Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. |
| Q38047053 | Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. |
| Q37066106 | Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape |
| Q27000087 | Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship |
| Q37532685 | Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients. |
| Q41143084 | Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer |
| Q37100179 | Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy |
| Q28131637 | Myeloid-derived suppressor cells as regulators of the immune system |
| Q37732211 | Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection |
| Q36332711 | Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells |
| Q38578686 | Myeloid-derived suppressor cells in B cell malignancies. |
| Q38116711 | Myeloid-derived suppressor cells in cancer: recent progress and prospects. |
| Q38509763 | Myeloid-derived suppressor cells in immunity and autoimmunity |
| Q33786718 | Myeloid-derived suppressor cells in sepsis |
| Q46064310 | Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties |
| Q38005601 | Myeloid-derived suppressor cells in transplantation and cancer |
| Q41952605 | Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves |
| Q34903354 | Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice |
| Q35852813 | Myeloid-derived suppressor cells participate in preventing graft rejection |
| Q37393000 | Myeloid-derived suppressor cells: a novel therapeutic target |
| Q24641811 | Myeloid-derived suppressor cells: linking inflammation and cancer |
| Q37786691 | Neutrophils: Cinderella of innate immune system |
| Q94467230 | New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry |
| Q35175098 | Obesity triggers enhanced MDSC accumulation in murine renal tumors via elevated local production of CCL2. |
| Q35077655 | Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice |
| Q38008023 | Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm? |
| Q38047052 | PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells |
| Q39405279 | Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner |
| Q37598872 | Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. |
| Q38579710 | Parallel Expression of Enzyme Inhibitors of CD8T Cell Activity in Tumor Microenvironments and Secretory Endometrium |
| Q28079046 | Phenotype, development, and biological function of myeloid-derived suppressor cells |
| Q34988287 | Phenotypic alteration of neutrophils in the blood of HIV seropositive patients |
| Q60935643 | Phenotypic and Functional Diversities of Myeloid-Derived Suppressor Cells in Autoimmune Diseases |
| Q64118067 | Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model |
| Q84156945 | Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer |
| Q35553327 | Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. |
| Q38718929 | Prevention and treatment of cancers by immune modulating nutrients. |
| Q35643918 | Protection by LPS-induced inhibitory CD11b(+) cells on corneal allograft |
| Q34492099 | Protein energy malnutrition increases arginase activity in monocytes and macrophages. |
| Q36796146 | Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy. |
| Q37889984 | Recent advances in immunotherapy for the treatment of prostate cancer |
| Q37997734 | Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer |
| Q26849305 | Regulation of immune responses by prostaglandin E2 |
| Q37806963 | Regulation of tumor immunity by tumor/dendritic cell fusions |
| Q89622533 | Reverting Immune Suppression to Enhance Cancer Immunotherapy |
| Q42283271 | Role of the tumor suppressor ARF in macrophage polarization: Enhancement of the M2 phenotype in ARF-deficient mice |
| Q47119947 | Serum Soluble Interleukin-2 Receptor is Increased in Malnourished and Immunosuppressed Patients With Gastric and Colorectal Cancer: Possible Influence of Myeloid-Derived Suppressor Cells |
| Q46375692 | Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice |
| Q90467233 | Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma |
| Q66226605 | Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. |
| Q92109460 | Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer |
| Q29614297 | Subsets of myeloid-derived suppressor cells in tumor-bearing mice |
| Q37412903 | Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment |
| Q61798869 | Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity |
| Q36809157 | TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation |
| Q39196835 | Tailored design of NKT-stimulatory glycolipids for polarization of immune responses |
| Q92511358 | Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors |
| Q47765346 | Targeting Myeloid-Derived Suppressor Cells in Cancer |
| Q92730933 | The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer |
| Q46279053 | The Regulation of Pathways of Inflammation and Resolution in Immune Cells and Cancer Stem Cells by Selenium |
| Q27860852 | The blockade of immune checkpoints in cancer immunotherapy |
| Q37413162 | The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. |
| Q34151972 | The growing diversity and spectrum of action of myeloid‐derived suppressor cells |
| Q38161874 | The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities |
| Q38649547 | The immunobiology of myeloid-derived suppressor cells in cancer |
| Q37253328 | The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression |
| Q47122830 | The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy |
| Q26783291 | The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy |
| Q44578886 | The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. |
| Q39567775 | The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis |
| Q38282450 | The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy |
| Q36946019 | The tumor microenvironment and its role in promoting tumor growth |
| Q34343645 | The tumor microenvironment in colorectal carcinogenesis |
| Q35947673 | Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. |
| Q55069007 | Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice. |
| Q37770271 | Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto- and alloimmunity |
| Q36796779 | Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells |
| Q37598949 | Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses |
| Q64290424 | Tumor infiltrating lymphocytes: The regulator of melanoma evolution |
| Q38067642 | Tumor microenvironment and myeloid-derived suppressor cells |
| Q37808467 | Tumor vaccines and beyond |
| Q38123166 | Tumor-altered dendritic cell function: implications for anti-tumor immunity |
| Q50997188 | Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. |
| Q35981563 | Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release |
| Q58780996 | Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression |
| Q39242385 | Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy |
| Q90468439 | Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression |
| Q89550303 | [Prediction of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation by the level of galectin-9 in peripheral blood] |
| Q92588804 | mTOR and Aging: An Old Fashioned Dress |
| Q26744447 | mTOR inhibitors effects on regulatory T cells and on dendritic cells |
| Q98778652 | miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells |
Search more.